Pimjetmi (pimicotinib)
- Region
- 🇺🇸 US
- Active substance
- pimicotinib
- Company
- Emd Serono
- Status
- Approved
- FDA approval
- Tue 10 Nov 2026
- Designations
- New molecular entity
- Application
- NDA220414
- Official record
- www.accessdata.fda.gov
Regulatory milestones
FDA approves Pimjetmi (pimicotinib), a new medicine
Emd Serono; NDA220414; New molecular entity; capsule · source
In-depth analysis
Where it stands
Pimjetmi (pimicotinib) is recorded as approved in the US. The FDA approval is dated 2026-11-10, and the sponsor is listed as Emd Serono. The official milestone describes it as a new medicine in capsule form, filed under NDA220414.
The records do not give the approved indication, so we cannot say which patients or condition the product is authorised for. The therapeutic area field is also blank. Any assessment of clinical positioning, label scope or competitive context would need the approved prescribing information, which is not in the records.
The CHMP opinion date is blank. The records contain no EU milestone, so the EU status of pimicotinib cannot be determined from this data. The only regulatory event recorded is the US approval.
Regulatory pathway and designations
The product was approved by the FDA under a New Drug Application (NDA220414). The only designation recorded is New molecular entity. In general, this means the active ingredient had not previously been approved in the US, so the application was a full review of a new active substance rather than of a known one.
The records do not show other pathway features, such as priority review, orphan status, breakthrough therapy designation, accelerated approval or any post-marketing requirements. Their absence from the records should not be read as meaning they do not apply, only that they are not documented here.
The records also do not give the submission date, the review timeline or the PDUFA goal date. The review duration and any extensions therefore cannot be assessed.
Safety and pharmacovigilance
The records contain no safety information. They list no boxed warning, contraindications, adverse-event profile, REMS or post-marketing safety commitments.
In general, a newly approved NME enters routine US pharmacovigilance on approval, including adverse event reporting and periodic safety reporting. Product-specific risks and any additional risk-minimisation measures can only be read from the approved label and review documents, which are not provided here.
What to watch
The first priority is to obtain the FDA approval letter and the prescribing information. These will confirm the indication, dosing, warnings and any post-marketing requirements or commitments that the records do not cover.
Second, check whether Emd Serono has filed or plans filings in other regions. The records show no CHMP opinion or EU milestone, so any EU timing is unknown from this data.
Third, once the label is available, track any early post-approval safety communications and label updates. The records do not indicate whether any are planned.
AI-generated on 2026-11-17 from the official records on this page (model claude-sonnet-5-5). It can contain errors: check the sources.
Follow Pimjetmi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.